These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Current drug therapy of systemic mycoses: a review. Yonga G East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014 [TBL] [Abstract][Full Text] [Related]
4. [Fungal esophagitis]. Péter Z; Telegdy L Orv Hetil; 2002 Jul; 143(29):1731-6. PubMed ID: 12198920 [TBL] [Abstract][Full Text] [Related]
5. [Systemic fungal infections in immunocompromised patients]. Zupanić-Krmek D; Nemet D Acta Med Croatica; 2004; 58(4):251-61. PubMed ID: 15700680 [TBL] [Abstract][Full Text] [Related]
6. Fungal infections in iatrogenically compromised hosts. Rex JH; Walsh TJ; Anaissie EJ Adv Intern Med; 1998; 43():321-71. PubMed ID: 9506187 [No Abstract] [Full Text] [Related]
7. Management of immunocompromised patients with evidence of an invasive mycosis. Walsh TJ Hematol Oncol Clin North Am; 1993 Oct; 7(5):1003-26. PubMed ID: 8226563 [TBL] [Abstract][Full Text] [Related]
8. Invasive candidiasis in immunocompromised hospitalized patients. Sims CR; Ostrosky-Zeichner L; Rex JH Arch Med Res; 2005; 36(6):660-71. PubMed ID: 16216647 [TBL] [Abstract][Full Text] [Related]
9. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. Metcalf SC; Dockrell DH J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716 [TBL] [Abstract][Full Text] [Related]
10. Fungal infections in neonates: update on prevention and treatment. Kaufman DA Minerva Ginecol; 2007 Jun; 59(3):311-29. PubMed ID: 17576407 [TBL] [Abstract][Full Text] [Related]
11. [Candida infections in immunocompromised hosts]. Wasak-Szulkowska E Pol Merkur Lekarski; 2005 Jul; 19(109):5-9. PubMed ID: 16194017 [TBL] [Abstract][Full Text] [Related]
12. Fungal infections associated with malignancies, treatments, and AIDS. Benedict S; Colagreco J Cancer Nurs; 1994 Oct; 17(5):411-7. PubMed ID: 7954389 [TBL] [Abstract][Full Text] [Related]
13. Strategies for managing systemic fungal infection and the place of itraconazole. Potter M J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634 [TBL] [Abstract][Full Text] [Related]
14. [Fungi in the intestine. Clinical significance]. Kreisel W Praxis (Bern 1994); 1999 Jan; 88(1-2):5-10. PubMed ID: 10067100 [No Abstract] [Full Text] [Related]
15. The place for itraconazole in treatment. Maertens J; Boogaerts M J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632 [TBL] [Abstract][Full Text] [Related]
16. Treatment of invasive fungal infections in immunocompromised patients with fluconazole. Esposito R; Uberti Foppa C; Cernuschi M J Chemother; 1989 Jul; 1(4 Suppl):925-6. PubMed ID: 16312707 [No Abstract] [Full Text] [Related]
17. [Efficacy of intravenous administration of itraconazole on fungal infections in immunocompromised patients with hematological diseases]. Wang JZ; Huang XJ; Liu KY; Liu DH; Chen H; Xu LP; Lu J; Zhang YC; Han W; Lu DP Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1481-3. PubMed ID: 16061027 [TBL] [Abstract][Full Text] [Related]
18. Evaluation and management of fungal infections in immunocompromised patients. Venkatesan P; Perfect JR; Myers SA Dermatol Ther; 2005; 18(1):44-57. PubMed ID: 15842612 [TBL] [Abstract][Full Text] [Related]
19. [Fungal infections in granulocytopenic and immunocompromised patients]. Schwenke H Z Gesamte Inn Med; 1992 Sep; 47(9):422-37. PubMed ID: 1441671 [TBL] [Abstract][Full Text] [Related]